Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation

Behavioural Pharmacology

Volumn 19, Issue 8, 2008, Pages 786-795

  Weber, Martin ^a   Chang, Wei li ^a   Breier, Michelle ^a   Ko, David ^a   Swerdlow, Neal R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

D2 receptor; D3 receptor; Dopemine; Epomorphine; L741,626; Pramipexole; Prepulse inhibition; Quinpirole; Rat strain

Indexed keywords

APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; L 741626; PRAMIPEXOLE; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; HEREDITY; LONG EVANS RAT; LOW DRUG DOSE; MALE; MOUSE STRAIN; NONHUMAN; PREPULSE INHIBITION; RAT; SENSORIMOTOR FUNCTION; SPRAGUE DAWLEY RAT; STARTLE REFLEX; STRAIN DIFFERENCE;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAIT DISORDERS, NEUROLOGIC; INDOLES; MALE; NEURAL INHIBITION; NUCLEUS ACCUMBENS; PIPERIDINES; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SENSORY GATING;

EID: 57149142243     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32831c3b2b     Document Type: Article

References (42)

1. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343.
2. Braff DL, Qeyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-268.
3. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL (2000). Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 157:1660-1668.
4. Caine SB, Geyer MA, Swerdlow NR (1995). Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Neuropsychopharmacology 12:139-145.
5. Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M (1996). Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 39:33-41.
6. Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C, et al. (2007). Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) 193:159-170.
7. Culm KE, Hammer RP Jr (2004). Recovery of sensorimotor gating without G protein adaptation after repeated D2-like dopamine receptor agonist treatment in rats. J Pharmacol Exp Ther 308:487-494.
8. Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ (2000). The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. Eur J Pharmacol 394:47-50.
9. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117-154.
10. Gottesman II, Gould TD (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160:636-645.
11. Graham FK (1975). Presidential address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 12:238-248.
12. Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40-68; image 5.
13. Joyce JN, Millan MJ (2005). Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925.
14. Kumari V, Das M, Zachariah E, Ettinger U, Sharrna T (2005). Reduced prepulse inhibition in unaffected siblings of schizophrenia patients. Psychophysiology 42:588-594.
15. Luedtke RR, Mach RH (2003). Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Des 9:643-671.
16. Maggio R, Scareelli M, Novi F, Millan MJ, Corsini GU (2003). Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 87:631-641.
17. Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 94:507-514.
18. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, et al. (2000). S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. receptorial, etectrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1048-1062.
19. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804.
20. Peng RY, Mansbach RS, Braff DL, Geyer MA (1990). A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology 3:211-218.
21. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK (1996). Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312: 35-44.
22. Saint Marie RL, Neary AC, Shoemaker JM, Swerdlow NR (2006). The effects of apomorphine and D-amphetamine on striatal c-Fos expression in Sprague-Dawley and Long-Evans rats and their F1 progeny. Brain Res 1119:203-214.
23. Saint Marie RL, Neary AC, Shoemaker J, Swerdlow NR (2007). Apomorphine effects on CREB phosphorylation in the nucleus accumbens of rat strains that differ in PPI sensitivity. Biol Psychiatry 61:37s.
24. Shilling PD, Saint Marie RL, Shoemaker J, Swerdlow NR (2008). Strain differences in gating-disruptive effects of apomorphine: relationship to accumbens gene expression. Biol Psychiatry 63:748-758.
25. Sokotoff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
26. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006). The dopamine D3 receptor a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25-43.
27. Sullivan PF (2005). The genetics of schizophrenia. PLoS Med 2:e212.
28. Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N (1994). Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol 263:235-243.
29. Swerdlow NR, Braff DL, Geyer MA, Koop GF (1986). Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry 21:23-33.
30. Swerdlow NR, Taaid N, Oostwegel JL, Randolph E, Geyer MA (1998). Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on propulse inhibition of acoustic startle in rats. Behav Pharmacol 9:389-396.
31. Swerdlow NR, Geyer MA, Braff DL (2001a). Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychepharmacology (Berl) 156:194-215.
32. Swerdlow NR, Platten A, Kim YK, Gaudet I, Shoemaker J, Pitcher L, Auerbach P (2001b). Sensitivity to the dopaminergic regulation of prepulse inhibition in rats: evidence for genetic, but not environmental determinants. Pharmacol Biochem Behav 70:219-226.
33. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Shoemaker J, Auerbach PP (2003). Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology 28: 640-650.
34. Swerdlow NR, Shoemaker JM, Auerbach PP, Pitcher L, Goins J, Platten A (2004a). Heritable differences in the dopaminergic regulation of sensorimotor gating. II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology (Berl) 174:452-462.
35. Swerdlow NR, Shoemaker JM, Grain S, Goins J, Onozuka K, Auerbach PP (2004b). Sensitivity to drug effects on prepulse inhibition in inbred and outbred rat strains. Pharmacol Biochem Behav 77:291-302.
36. Swerdlow NR, Shoemaker JM, Platten A, Pitcher L, Goins J, Auerbach PP (2004c). Heritable differences in the dopaminergic regulation of sensorimotor gating. I. Apomorphine effects on startle gating in albino and hooded outbred rat strains and their F1 and N2 progeny. Psychopharmacology (Berl) 174:441-451.
37. Swerdlow NR, Krupin AS, Bongiovanni MJ, Shoemaker JM, Goins JC, Hammer RP Jr (2006). Heritable differences in the dopaminergic regulation of behavior in rats: relationship to D2-like receptor G-protein function. Neuropsychopharmacology 31:721-729.
38. Swerdlow NR, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL (2007). Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. Pharmacol Biochem Behav 87:1-10.
39. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR (2007). Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33:69-94.
40. Varty GB, Higgins GA (1998). Dopamine agonist-induced hypothermia and disruption of prepulse inhibition: evidence for a role of D3 receptors? Behav Pharmacol 9:445-455.
41. Weber M, Swerdlow NR (2008). Rat strain differences in startle gating-disruptive effects of apomorphine occur with both acoustic and visual prepulses. Pharmacol Biochem Behav 88:306-311.
42. Zhang M, Ballard ME, Linger LV, Haupt A, Gross G, Decker MW, et al. (2007). Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res 182:1-11.